GLTO Quote, Financials, Valuation and Earnings

Cogent Biosciences, Inc. has a net margin of -- compared to Galecto, Inc.'s net margin of --. Galecto, Inc.'s return on equity of -123.72% beat Cogent Biosciences, Inc.'s return on equity of -117.99%.

Galecto, Inc. has a consensus price target of $41.00, signalling upside risk potential of 38.61%. On the other hand Cogent Biosciences, Inc. has an analysts' consensus of $50.67 which suggests that it could grow by 28.17%. Given that Galecto, Inc. has higher upside potential than Cogent Biosciences, Inc., analysts believe Galecto, Inc. is more attractive than Cogent Biosciences, Inc..

Galecto, Inc. has a beta of 1.417, which suggesting that the stock is 41.723% more volatile than S&P 500. In comparison Cogent Biosciences, Inc. has a beta of 0.504, suggesting its less volatile than the S&P 500 by 49.585%.

Galecto, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cogent Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Galecto, Inc. pays -- of its earnings as a dividend. Cogent Biosciences, Inc. pays out -- of its earnings as a dividend.

Galecto, Inc. quarterly revenues are --, which are smaller than Cogent Biosciences, Inc. quarterly revenues of --. Galecto, Inc.'s net income of -$3.1M is higher than Cogent Biosciences, Inc.'s net income of -$80.9M. Notably, Galecto, Inc.'s price-to-earnings ratio is -- while Cogent Biosciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Galecto, Inc. is -- versus 55.99x for Cogent Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Ionis Pharmaceuticals, Inc. has a net margin of -- compared to Galecto, Inc.'s net margin of -82.06%. Galecto, Inc.'s return on equity of -123.72% beat Ionis Pharmaceuticals, Inc.'s return on equity of -43.01%.

Galecto, Inc. has a consensus price target of $41.00, signalling upside risk potential of 38.61%. On the other hand Ionis Pharmaceuticals, Inc. has an analysts' consensus of $90.63 which suggests that it could grow by 10.8%. Given that Galecto, Inc. has higher upside potential than Ionis Pharmaceuticals, Inc., analysts believe Galecto, Inc. is more attractive than Ionis Pharmaceuticals, Inc..

Galecto, Inc. has a beta of 1.417, which suggesting that the stock is 41.723% more volatile than S&P 500. In comparison Ionis Pharmaceuticals, Inc. has a beta of 0.278, suggesting its less volatile than the S&P 500 by 72.158%.

Galecto, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ionis Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Galecto, Inc. pays -- of its earnings as a dividend. Ionis Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Galecto, Inc. quarterly revenues are --, which are smaller than Ionis Pharmaceuticals, Inc. quarterly revenues of $156.7M. Galecto, Inc.'s net income of -$3.1M is higher than Ionis Pharmaceuticals, Inc.'s net income of -$128.6M. Notably, Galecto, Inc.'s price-to-earnings ratio is -- while Ionis Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Galecto, Inc. is -- versus 13.93x for Ionis Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Ovid Therapeutics, Inc. has a net margin of -- compared to Galecto, Inc.'s net margin of -9210.61%. Galecto, Inc.'s return on equity of -123.72% beat Ovid Therapeutics, Inc.'s return on equity of -59.7%.

Galecto, Inc. has a consensus price target of $41.00, signalling upside risk potential of 38.61%. On the other hand Ovid Therapeutics, Inc. has an analysts' consensus of $4.05 which suggests that it could grow by 131.37%. Given that Ovid Therapeutics, Inc. has higher upside potential than Galecto, Inc., analysts believe Ovid Therapeutics, Inc. is more attractive than Galecto, Inc..

Galecto, Inc. has a beta of 1.417, which suggesting that the stock is 41.723% more volatile than S&P 500. In comparison Ovid Therapeutics, Inc. has a beta of 0.216, suggesting its less volatile than the S&P 500 by 78.387%.

Galecto, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ovid Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Galecto, Inc. pays -- of its earnings as a dividend. Ovid Therapeutics, Inc. pays out -- of its earnings as a dividend.

Galecto, Inc. quarterly revenues are --, which are smaller than Ovid Therapeutics, Inc. quarterly revenues of $132K. Galecto, Inc.'s net income of -$3.1M is higher than Ovid Therapeutics, Inc.'s net income of -$12.2M. Notably, Galecto, Inc.'s price-to-earnings ratio is -- while Ovid Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Galecto, Inc. is -- versus 18.82x for Ovid Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of -- compared to Galecto, Inc.'s net margin of 38.89%. Galecto, Inc.'s return on equity of -123.72% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 15.37%.

Galecto, Inc. has a consensus price target of $41.00, signalling upside risk potential of 38.61%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $830.04 which suggests that it could grow by 9.87%. Given that Galecto, Inc. has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe Galecto, Inc. is more attractive than Regeneron Pharmaceuticals, Inc..

Galecto, Inc. has a beta of 1.417, which suggesting that the stock is 41.723% more volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.390, suggesting its less volatile than the S&P 500 by 60.965%.

Galecto, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.47% to investors and pays a quarterly dividend of $0.88 per share. Galecto, Inc. pays -- of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Galecto, Inc. quarterly revenues are --, which are smaller than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.8B. Galecto, Inc.'s net income of -$3.1M is lower than Regeneron Pharmaceuticals, Inc.'s net income of $1.5B. Notably, Galecto, Inc.'s price-to-earnings ratio is -- while Regeneron Pharmaceuticals, Inc.'s PE ratio is 18.09x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Galecto, Inc. is -- versus 5.84x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.